iShares Biotechnology ETF
609 hedge funds and large institutions have $6.14B invested in iShares Biotechnology ETF in 2018 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 171 increasing their positions, 227 reducing their positions, and 59 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
8% less funds holding in top 10
Funds holding in top 10: 25 → 23 (-2)
17% less call options, than puts
Call options by funds: $411M | Put options by funds: $495M
25% less repeat investments, than reductions
Existing positions increased: 171 | Existing positions reduced: 227
Holders
609
Holding in Top 10
23
Calls
$411M
Puts
$495M
Top Buyers
| 1 | +$169M | |
| 2 | +$167M | |
| 3 | +$70.1M | |
| 4 |
Citigroup
New York
|
+$64.6M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$33.6M |
Top Sellers
| 1 | -$50.5M | |
| 2 | -$39.2M | |
| 3 | -$26.7M | |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$22.5M |
| 5 |
SF
Synovus Financial
Columbus,
Georgia
|
-$21.3M |